11,250 results match your criteria Acromegaly

Quality of life and response to treatment in cats with hypersomatotropism: the owners' point of view.

J Feline Med Surg 2022 May 26:1098612X221098718. Epub 2022 May 26.

Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell'Emilia, Italy.

Objectives: The aim of this study was to collect clinical information from owners of cats with hypersomatotropism (HS) distributed worldwide, assessing the impact of HS and its treatments on cats' quality of life (QoL) and survival time.

Methods: A survey focused on clinical presentation, diagnostic procedures, treatments, cats' QoL and disease progression was distributed worldwide to owners of cats with HS. The owner's perception of the cats' QoL before and after or during treatment was defined using a score ranging from 1 (poor) to 5 (excellent). Read More

View Article and Full-Text PDF

Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature.

Arch Endocrinol Metab 2022 May 25. Epub 2022 May 25.

University of Health Sciences, Diskapi Training and Research Hospital, Department of Endocrinology and Metabolism, Ankara, Turkey.

Objective: It is reported that adding cabergoline to somatostatin analog (SSA) normalizes IGF-1 levels approximately in one-third of patients with acromegaly. We investigated the effect of combination therapy and potential predictors of response in patients with acromegaly who do not respond to SSA therapy alone.

Methods: Fifty acromegaly patients (M/F 23/27, mean age 50. Read More

View Article and Full-Text PDF

Minimizing the initial burst of octreotide acetate based long-acting microspheres by the solvent evaporation method.

Int J Pharm 2022 May 21:121842. Epub 2022 May 21.

Department of Pharmaceutical Sciences and the Biointerfaces Institute, University of Michigan, 2800 Plymouth Road, Ann Arbor, MI 48109; Department of Biomedical Engineering, University of Michigan, 2200 Bonisteel Blvd, Ann Arbor, MI 48109. Electronic address:

Sandostatin long-acting release (SLAR) depot for 1-month controlled release of octreotide is a somatostatin analogue product that has been used extensively in the pharmacological treatment of acromegaly. The complexities in the SLAR coacervation manufacturing processes and the use of a unique glucose-starpoly(lactic-co-glycolic acid) (PLGA-glu) may have contributed to the lack of US FDA-approved generic products referencing SLAR in the USA. To address this challenge, we encapsulated octreotideacetate by commonly used solvent evaporation methodin microspheres of a similar composition to SLAR, including the use of a comparable PLGA-glu. Read More

View Article and Full-Text PDF

Biochemical discrepancies in the evaluation of the somatotroph axis: Elevated GH or IGF-1 levels do not always diagnose acromegaly.

Growth Horm IGF Res 2022 May 17;64:101467. Epub 2022 May 17.

Endocrinology Department, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte, Lisbon, Portugal; Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK. Electronic address:

The most frequent diagnosis underlying the finding of an elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) is acromegaly due to a GH-secreting pituitary tumour. However, GH and IGF-1 levels can be discordant in patients with acromegaly due to early or partially treated disease, or there might be another cause of high GH or high IGF-1 unrelated to acromegaly, such as pre-analytical and technical pitfalls, physiological circumstances and pathological conditions. High GH and normal or low serum IGF-1, or alternatively, normal GH with elevated serum IGF-1, should be carefully assessed to avoid misinterpreting the activity of acromegaly or misdiagnosing a patient with acromegaly. Read More

View Article and Full-Text PDF

Cancer prevalence and cancer screening in patients with acromegaly: a single center experience.

Endocrine 2022 May 24. Epub 2022 May 24.

Ondokuz Mayis University, Faculty of Medicine, Department of Endocrinology and Metabolism, Samsun, Turkey.

Purpose: To investigate the prevalence of cancer in patients with acromegaly and the variables associated with malignant and premalignant lesions detected by cancer screening.

Methods: The data of 214 patients diagnosed with acromegaly in our institution were evaluated retrospectively. Prevalence of cancer was compared with national rates to estimate standardized incidence ratios (SIRs). Read More

View Article and Full-Text PDF

Complicated Clinical Course in Incipient Gigantism Due to Treatment-resistant Aryl Hydrocarbon Receptor-Interacting Protein-mutated Pediatric Somatotropinoma.

AACE Clin Case Rep 2022 May-Jun;8(3):119-123. Epub 2021 Dec 16.

Department of Internal Medicine, Endocrinology; Erasmus Medical Center, Rotterdam, The Netherlands.

Background: Our objective was to describe the clinical course and treatment challenges in a very young patient with a pituitary adenoma due to a novel gene mutation, highlighting the limitations of somatostatin receptor immunohistochemistry to predict clinical responses to somatostatin analogs in acromegaly.

Case Report: We report the case of a 7-year-old boy presenting with headache, visual field defects, and accelerated growth following failure to thrive. The laboratory results showed high insulin-like growth factor I (IGF-I) (standardised deviation scores ( +3. Read More

View Article and Full-Text PDF
December 2021

Stigma and unhealthy psychological characteristics in patients with acromegaly: A cross-sectional study and identification of the associated factors.

Acta Neurochir (Wien) 2022 May 21. Epub 2022 May 21.

Department of Nursing, Affiliated Hospital of Nantong University, 20th Xisi Road, Nantong, 226001, China.

Background: Stigma, besides aggravating the damage caused by the disease, may also lead to unhealthy characteristics in patients and unhealthy situations in society. Individuals with acromegaly disease may suffer from stigma concerns, and the associated factors remain largely unknown. Therefore, the present cross-sectional study aimed to investigate the levels of perceived stigma in patients with acromegaly and explore the associated factors. Read More

View Article and Full-Text PDF

Clinical and functional outcome of total hip arthroplasty in patients with acromegaly: mean twelve year follow-up.

Int Orthop 2022 May 21. Epub 2022 May 21.

Department of Orthopaedic Surgery, Helios ENDO-Klinik, Hamburg, Germany.

Purpose: Acromegaly is a rare and chronic hormonal disorder. Persons with acromegaly frequently live well into adulthood. Patients with active acromegaly have multiple joint-related issues; however, acromegalic arthropathy (AA), which is secondary osteoarthritis (OA), is considered one of the most common musculoskeletal complications of acromegaly. Read More

View Article and Full-Text PDF

Patient's point of view on the diagnosis, treatment, and follow-up in acromegaly: single-center study from a tertiary center.

Rev Assoc Med Bras (1992) 2022 May;68(5):599-604

Ankara Yıldırım Beyazıt University, Faculty of Medicine, Department of Endocrinology and Metabolic Disease - Çankaya, Turkey.

Objective: We aimed to evaluate the awareness and perspectives of acromegaly patients in the diagnosis and treatment processes and to evaluate basic clinical and demographic features.

Methods: This cross-sectional study was conducted at the Endocrinology Department of Yildirim Beyazit University between March 2019 and April 2020. A total of 58 acromegalic patients were enrolled. Read More

View Article and Full-Text PDF

A new device for remote monitoring of vital parameters in acromegalic patients: pilot study.

Endocr Metab Immune Disord Drug Targets 2022 May 16. Epub 2022 May 16.

Department of Experimental Medicine, Endocrinology, Sapienza- University of Rome.

Introduction: Acromegaly is a rare disease which results from growth hormone (GH) excess. Diabetes mellitus, hypertension, cardiomyopathy and obstructive sleep apnoea syndrome (OSAS) are frequent complications.

Aim Of The Study: Identify a useful system to obtain a reliable remote monitoring of glucose and the most important vital parameters in the acromegalic subjects. Read More

View Article and Full-Text PDF

Eye symptoms in acromegaly, beyond visual field alteration.

Endocrinol Diabetes Nutr (Engl Ed) 2022 May 12. Epub 2022 May 12.

Servicio Oftalmología, Complejo Hospitalario Universitario de Ferrol, CHUF, Ferrol, La Coruña, Spain.

View Article and Full-Text PDF

The value of intraoperative MRI for resection of functional pituitary adenomas-a critical assessment of a consecutive single-center series of 114 cases.

Neurosurg Rev 2022 May 14. Epub 2022 May 14.

Department of Neurosurgery, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.

This series sought to evaluate the role of intraoperative MRI (iMRI) for resection of functional pituitary adenomas (FPAs). We retrospectively reviewed clinical data of 114 consecutive FPAs with excessive hormone secretion treated with transsphenoidal surgery and iMRI during 01/2010-12/2017. We focused on iMRI findings, extend of resection and postoperative hormonal remission. Read More

View Article and Full-Text PDF

Determining airflow obstruction from tracheal sound analysis: simulated tests and evaluations in patients with acromegaly.

Med Biol Eng Comput 2022 May 10. Epub 2022 May 10.

Biomedical Instrumentation Laboratory, Institute of Biology and Faculty of Engineering, State University of Rio de Janeiro, Rio de Janeiro, Brazil.

To evaluate the ability of tracheal sound analysis (TSA) to detect airflow obstruction, particularly in patients with acromegaly. A simulated analysis compared free airflow conditions with airflow through orifice plates 6, 8, 10 and 12 mm in diameter. Based on these results, TSA and spirometry examinations were performed on controls (n = 17) and patients with acromegaly (n = 17). Read More

View Article and Full-Text PDF


Acta Clin Croat 2021 Dec;60(Suppl 2):17-26

National Monitoring Committee for the Implementation of the National Colon Cancer Early Detection Program of the Croatian Ministry of Health, Zagreb, Croatia.

Colorectal cancer is a malignant neoplasm which has an increasing incidence and represents a global public health problem. The majority of patients are diagnosed after the age of 50, and the risk of developing it over lifetime is 5%. Development of preventive, diagnostic and treatment methods has resulted in a significant reduction in mortality and other negative clinical outcomes. Read More

View Article and Full-Text PDF
December 2021

Trabecular Bone Score and Osteoprotegerin as Useful Tools in the Assessment of Bone Deterioration in Acromegaly.

Front Endocrinol (Lausanne) 2022 21;13:862845. Epub 2022 Apr 21.

Department and Clinic of Endocrinology, Diabetes and Isotope Therapy, Medical University, Wrocław, Poland.

Purpose: This study aimed to assess bone mineral density (BMD) and trabecular bone score (TBS) in 61 patients from the acromegaly group (AG) with regard to the activity of the disease in comparison to 42 patients-control group (CG). We also analyzed selected bone markers and their association with BMD and TBS.

Materials And Methods: Lumbar spine and femoral neck BMD measurements were performed. Read More

View Article and Full-Text PDF

Pituitary MRI Features in Acromegaly due to Ectopic GHRH Secretion from a Neuroendocrine Tumor: Analysis of 30 cases.

J Clin Endocrinol Metab 2022 May 4. Epub 2022 May 4.

Endocrinology and Nutrition Department, Complejo Hospitalario Universitario de Santiago de Compostela, Galicia, Spain.

Context: Ectopic acromegaly is a consequence of rare neuroendocrine tumors (NET) that secrete growth hormone releasing hormone (GHRH). This abnormal GHRH secretion drives growth hormone (GH) and insulin-like growth factor 1 (IGF-1) excess, with a clinical presentation similar to classical pituitary acromegaly. Identifying the underlying cause for the GH hypersecretion in the setting of ectopic GHRH excess is, however, essential for proper management both of acromegaly and the NET. Read More

View Article and Full-Text PDF

The Internal Cranial Anatomy of a Female With Endocrine Disorders From a Mediaeval Population.

Front Endocrinol (Lausanne) 2022 14;13:862047. Epub 2022 Apr 14.

PaleoFED Team, Unité Mixte de Recherche (UMR) 7194, Centre National de la Recherche Scientifique (CNRS), Département Homme et Environnement, Muséum National d'Histoire Naturelle, Musée de l'Homme, Paris, France.

Gigantism and acromegaly have been observed in past populations; however, analyses usually focus on the morphological features of the post-cranial skeleton. The aim of this study is to characterize the internal anatomical features of the skull (brain endocast anatomy and asymmetry, frontal pneumatization, cranial thickness, sella turcica size) of an adult individual from the 11-14th centuries with these two diseases, in comparison with non-pathological individuals from the same population. The material consisted of 33 adult skulls from a mediaeval population, one of them belonging to an adult female with endocrine disorders (OL-23/77). Read More

View Article and Full-Text PDF

Surgical Outcome and Evaluation of Strategies in the Management of Growth Hormone-Secreting Pituitary Adenomas After Initial Transsphenoidal Pituitary Adenectomy Failure.

Front Endocrinol (Lausanne) 2022 14;13:756855. Epub 2022 Apr 14.

Department of Neurosurgery, Keelung Chang Gung Memorial Hospital of the Chang Gung Medical Foundation, Keelung, Taiwan.

Acromegaly is a systemic disease that requires multidisciplinary treatment to achieve the best clinical outcome. This study aimed to evaluate the outcomes of the endoscopic transsphenoidal approach (TSA) as the primary treatment for somatotroph adenomas and further investigate patients who had suboptimal surgical results. This retrospective study included 83 patients with somatotroph adenomas treated by TSA at our institution from 1999 to 2010. Read More

View Article and Full-Text PDF

Characteristics and treatment outcomes of micromegaly - acromegaly with apparently normal basal GH: A retrospective study and literature review.

Endocr Regul 2022 Apr 30;56(2):87-94. Epub 2022 Apr 30.

Endocrinology Department, Centro Hospitalar Universitario do Porto, Porto, Portugal.

Micromegaly describes a subgroup of patients with clinically evident acromegaly and elevated insulin-like growth factor I (IGF-I) with apparently normal basal growth hormone (bGH) and often a glucose-suppressed growth hormone (GH) of <1 ng/mL at diagnosis. It is controversial whether this condition is a distinct clinical entity or a classic acromegaly in early stages. The aim of the present article was to characterize the prevalence, clinical and biochemical characteristics, and therapeutic outcomes of micromegaly. Read More

View Article and Full-Text PDF

The biochemical diagnosis of acromegaly: revising the role of measurement of IGF-I and GH after glucose load in 5 questions.

Expert Rev Endocrinol Metab 2022 Apr 29:1-20. Epub 2022 Apr 29.

Division of Endocrinology Diabetes and Metabolism and Pituitary Center, Johns Hopkins University, Baltimore MD, USA.

Introduction: Acromegaly is a rare disorder characterized by the excessive secretion of growth hormone (GH), mostly caused by pituitary adenomas. While in full-blown cases the diagnosis is easy to establish, milder cases are more challenging. Additionally, establishing whether full cure after surgery is reached may be difficult. Read More

View Article and Full-Text PDF

Quality of life after long-term biochemical control of acromegaly.

Pituitary 2022 Apr 27. Epub 2022 Apr 27.

Neuroendocrine Unit, Massachusetts General Hospital, 55 Fruit Street, Bulfinch 457, Boston, MA, 02114, USA.

Purpose: To assess long-term quality of life (QoL) in patients with sustained biochemical control of acromegaly, comparing those receiving vs not receiving pharmacotherapy (primary analysis); to assess change in QoL over time (secondary analysis).

Methods: Cross-sectional study, with a secondary longitudinal component, of 58 patients with biochemically controlled acromegaly. All had participated in studies assessing QoL years previously, after having undergone surgery ± radiotherapy. Read More

View Article and Full-Text PDF

Application of Virtual Surgical Planning to Reduction Mandibuloplasty for Mandibular Hyperplasia Secondary to Acromegaly.

Plast Reconstr Surg Glob Open 2022 Apr 22;10(4):e4173. Epub 2022 Apr 22.

Medstar Georgetown University Hospital, Washington, D.C.

View Article and Full-Text PDF

Sex difference in patients with controlled acromegaly-A multicentre survey.

Clin Endocrinol (Oxf) 2022 Apr 26. Epub 2022 Apr 26.

Department of Endocrinology, Aarhus University Hospital, Aarhus C, Denmark.

Objective: Active acromegaly is subject to sex differences in growth hormone (GH) and Insulin like growth factor 1 (IGF-I) patterns as well as clinical features but whether this also pertains to controlled disease is unclear.

Design: In a cross-sectional, multi-centre study, 84 patients with acromegaly (F = 43, M = 41), who were considered controlled after surgery alone (n = 23) or during continued somatostatin receptor ligand (SRL) treatment (n = 61), were examined.

Methods: Serum concentrations of GH, insulin, glucose and free fatty acid (FFA) were measured during an oral glucose tolerance test (OGTT) together with baseline serum IGF-I and completion of two HR-Qol questionnaires (acromegaly quality of life questionnaire [AcroQol] and Patient-assessed Acromegaly Symptom Questionnaire [PASQ]). Read More

View Article and Full-Text PDF

Efficacy of lanreotide 120 mg primary therapy on tumour shrinkage and ophthalmologic symptoms in acromegaly after 1 month.

Clin Endocrinol (Oxf) 2022 Apr 25. Epub 2022 Apr 25.

Department of Endocrinology, Diabetology, and Metabolism, Lille University Hospital, Lille, France.

Introduction: Few studies have attempted to evaluate the early efficacy of first-generation somatostatin analogues in somatotroph macroadenomas.

Objective: To investigate the short-term efficacy of primary therapy with lanreotide 120 mg at 1 and 3 months on tumour shrinkage and ophthalmologic symptoms in newly diagnosed patients with acromegaly.

Design And Patients: This single-centre retrospective study included 21 patients with de novo acromegaly resulting from pituitary macroadenoma, with optic chiasm compression (Grade ≤ 2) and/or cavernous sinus invasion, treated with a monthly injection of lanreotide 120 mg. Read More

View Article and Full-Text PDF

Acromegaly is associated with a distinct oral and gut microbiota.

Pituitary 2022 Apr 25. Epub 2022 Apr 25.

Department of Endocrinology and Metabolic Diseases, School of Medicine, Yeditepe University, Istanbul, Turkey.

Purpose: Our aim was to investigate the changes in the composition of oral and gut microbiota in patients with newly diagnosed acromegaly and their relationship with IGF-1 levels.

Methods: Oral and fecal samples were collected from patients with newly diagnosed acromegaly without comorbidities and from healthy controls. The composition of the microbiota was analyzed. Read More

View Article and Full-Text PDF

Neurofibromatosis Type 1 Has a Wide Spectrum of Growth Hormone Excess.

J Clin Med 2022 Apr 13;11(8). Epub 2022 Apr 13.

Section on Endocrinology & Genetics (SEGEN), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, MD 20892, USA.

Overgrowth due to growth hormone (GH) excess affects approximately 10% of patients with neurofibromatosis type 1 (NF1) and optic pathway glioma (OPG). Our aim is to describe the clinical, biochemical, pathological, and genetic features of GH excess in a retrospective case series of 10 children and adults with NF1 referred to a tertiary care clinical research center. Six children (median age = 4 years, range of 3-5 years), one 14-year-old adolescent, and three adults (median age = 42 years, range of 29-52 years) were diagnosed with NF1 and GH excess. Read More

View Article and Full-Text PDF

Oral Octreotide: A Review of Recent Clinical Trials and Practical Recommendations for Its Use in the Treatment of Patients With Acromegaly.

Endocr Pract 2022 Apr 19. Epub 2022 Apr 19.

Departments of Medicine and Neurologic Surgery, Mayo Clinic, Jacksonville, Florida.

Objective: Acromegaly is characterized by chronic growth hormone (GH) and insulin-like growth factor 1 (IGF-1) hypersecretion, often caused by a GH-secreting pituitary adenoma. Even though surgery remains the first line of treatment, medical therapy is essential if surgery is contraindicated, does not achieve remission, or does not prevent recurrence despite apparent surgical remission. Oral octreotide capsules (OOCs) that combine octreotide with a transient permeability enhancer technology are the first oral somatostatin receptor ligands (SRLs) approved in the United States for acromegaly. Read More

View Article and Full-Text PDF

Clinico-radiological features of acromegaly-related cutis verticis gyrata.

Hormones (Athens) 2022 Apr 18. Epub 2022 Apr 18.

Endocrinology Department, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte, Av. Prof. Egas Moniz, 1649-028, Lisbon, Portugal.

View Article and Full-Text PDF

Machine learning as a clinical decision support tool for patients with acromegaly.

Pituitary 2022 Apr 18. Epub 2022 Apr 18.

Department of Internal Medicine, Division of Endocrinology, Metabolism, and Diabetes, Cerrahpasa Medical School, Istanbul University-Cerrahpaşa, Kocamustafapaşa Street No:53, 34098 Fatih, Istanbul, Turkey.

Objective: To develop machine learning (ML) models that predict postoperative remission, remission at last visit, and resistance to somatostatin receptor ligands (SRL) in patients with acromegaly and to determine the clinical features associated with the prognosis.

Methods: We studied outcomes using the area under the receiver operating characteristics (AUROC) values, which were reported as the performance metric. To determine the importance of each feature and easy interpretation, Shapley Additive explanations (SHAP) values, which help explain the outputs of ML models, are used. Read More

View Article and Full-Text PDF

Clinical Applicability of Patient- and Clinician-Reported Outcome Tools in the Management of Patients With Acromegaly.

Endocr Pract 2022 Apr 11. Epub 2022 Apr 11.

Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia; Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. Electronic address:

Objective: We aimed to assess treatment outcomes and disease control status in patients with acromegaly using patient- and clinician-reported outcome tools and to analyze correlations among different components of both tools.

Methods: This cross-sectional study included 72 patients from a national referral center with a median follow-up of 8 (5-12) years. The baseline SAGIT score at diagnosis was determined retrospectively, whereas the follow-up SAGIT and acromegaly quality of life questionnaire (AcroQoL) results were assessed at the most recent visit and by additional telephone interviews. Read More

View Article and Full-Text PDF